Scores of attempts have been made to deliver biologics orally, and most have failed. We believe Rani’s approach will transform the market, and we are on the way to proving that it is nothing short of a breakthrough. Rani has successfully:
Octreotide can lower levels of excess growth hormone for the treatment of acromegaly, a disorder characterized by enlargement of face, hands and feet. It can also treat diarrhea associated with certain types of tumors. The Rani platform could eliminate injections for these patients and replace them with a daily pill.
In contrast to these prior attempts, the RaniPill capsule delivers biologics with high bioavailability, similar to subcutaneous injection, in the range of 40% to 78%, with high dosing accuracy. We are early in our development efforts and have only one product candidate, RT-101, in early clinical development. In our Phase 1 clinical trial of RT-101, we tested the RaniPill capsule in a limited number of healthy volunteers.
TNF-alpha (TNFα) inhibitors are used to treat a number of inflammatory disorders and autoimmune conditions including psoriasis, rheumatoid arthritis and Crohn’s disease. A Rani product could transform this therapy replacing painful, biweekly injections with a daily pill.
There are several medications available for the prevention or treatment of osteoporosis, however, PTH is the most-effective and the only bone-building treatment. Hypoparathyroidism is a rare condition of low levels of serum PTH resulting in low calcium levels in the blood. PTH is currently approved for the treatment of hypoparathyroidism by the FDA and EMA and requires lifelong daily injections but has suboptimal efficacy.
Human Growth Hormone (HGH) is a peptide hormone that stimulates growth, cell reproduction and regeneration, and is used in the treatment of growth disorders and growth deficiency. A Rani product could transform this therapy replacing painful weekly or daily injections with daily pills.
Glucagon-like peptide-1 agonists or GLP-1 mimetics are a class of drugs used in the treatment of Type II diabetes and obesity. Available GLP-1 agonists include exenatide, liraglutide and lixisenatide. Currently, patients must administer a daily or weekly injection. The Rani platform could transform this therapy with daily pills.
Basal insulin or “background insulin” is used in diabetes management as a way to regulate glucose levels in between meals. The RaniPill™ could change the lives of millions of diabetes patients by radically reducing the amount and frequency of injections.
“Millions must take injections to slow the progression of their condition. With pills, compliance is much higher than with injections which helps slow down chronic diseases.”
“I am passionate about changing healthcare and coming up with new solutions that will impact the lives of millions of patients.”
“Given the market demand and potential, it’s no wonder that there have been countless attempts and dollars spent by companies to try to convert painful injections into painless pills.”